Protein S

Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

Retrieved on: 
星期二, 五月 23, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Protein S, VWD, Thrombin, Von Willebrand disease, MD, Patient, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, EU

Vega Therapeutics , Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for VGA039 for the treatment of the rare bleeding disorder, von Willebrand disease (VWD).

Key Points: 
  • Vega Therapeutics , Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for VGA039 for the treatment of the rare bleeding disorder, von Willebrand disease (VWD).
  • By promoting thrombin generation through targeting Protein S, VGA039 addresses a fundamental mechanism of clot formation in VWD and, as a subcutaneously self-administered antibody therapy, has potential to transform VWD treatment.
  • “Receiving orphan drug designation status is an important step for VGA039,” said Gary Patou, MD, Chief Medical Officer of Vega Therapeutics.
  • In preclinical studies, VGA039 has demonstrated efficacy in VWD, as well as in numerous congenital bleeding disorders.

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First‑in‑Class Antibody Therapy for von Willebrand Disease

Retrieved on: 
星期四, 四月 6, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, University of Texas Southwestern Medical Center, University, Protein S, VWD, Vega, CTA, Coagulopathy, Trial of the century, Von Willebrand disease, MD, Patient, Coagulation, Quebec platelet disorder, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

Vega Therapeutics , Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated.

Key Points: 
  • Vega Therapeutics , Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated.
  • The clinical trial program will begin with enrollment of healthy volunteers and expand to include patients with von Willebrand disease (VWD).
  • By promoting thrombin generation through targeting Protein S, VGA039 addresses a fundamental mechanism of clot formation in VWD and, as a subcutaneously self-administered antibody therapy, has potential to transform VWD treatment.
  • Vega plans to enroll the Phase 1 clinical trial for VGA039 at clinical trial sites across the U.S. and other countries.

Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting

Retrieved on: 
星期二, 十二月 6, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, Therapy, Norwest Venture Partners, RA, SC, Clinical trial, MD, Haemophilia, Coagulation, Doctor of Philosophy, Competent authority, Society, Patient, Entrepreneurship, Thrombin, Biology, Vega, APC, Coagulopathy, Von Willebrand factor, Bleeding, VWF, VWD, Trial of the century, Von Willebrand disease, Fibrinolysis, Degenerative disease, Pharmacokinetics, Blood, ASH, Protein S, Pharmaceutical industry

Vega was spun out of its parent company, Star Therapeutics , to advance the discovery and development of antibody therapies for patients with blood disorders, starting with von Willebrand disease (VWD).

Key Points: 
  • Vega was spun out of its parent company, Star Therapeutics , to advance the discovery and development of antibody therapies for patients with blood disorders, starting with von Willebrand disease (VWD).
  • Vega will disclose the first public information about VGA039 in a podium presentation on December 12th at the ASH Annual Meeting in New Orleans.
  • In VWD, defective or low amounts of von Willebrand factor (VWF) leads to insufficient platelet adhesion and unstable clot formation.
  • Vega Therapeutics is a clinical stage biotechnology company developing novel, first-in-class therapies for rare blood disorders with overlooked patient needs, starting with von Willebrand disease (VWD).

2022 U.S. Coagulation Testing Market Report: Identify and Evaluate Emerging Business Opportunities - ResearchAndMarkets.com

Retrieved on: 
星期二, 十一月 1, 2022
Research, Managed Care, General Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Surgery, Biotechnology, Other Science, Health, ACT, Factor VII, Factor XII, Factor, Factor XI, Factor IX, APTT, Protein S, Activated protein C resistance, Thrombin time, Antithrombin, Bleeding time, Protein C, Factor X, Prothrombin time, Consumables, Factor V, Factor VIII, Prekallikrein, Comparison, Factor XIII, Fibrinogen, Marketing, Retail, Vaccine, Fine chemical, Pharmaceutical industry, Plasmin

The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities in the US coagulation testing market during the next five years.
  • The report is available by section, and can be customized to specific information needs and budget.
  • The report explores business and technological trends in the US coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Global Coagulation Testing Lab and POC Market (2022 to 2026) - Analysis of Current and Emerging Technologies and Their Potential Market Applications - ResearchAndMarkets.com

Retrieved on: 
星期二, 四月 26, 2022
Health, Medical Devices, Cardiology, ACT, Computer, Factor VII, Factor IX, APTT, Thrombin time, Factor XIII, Coagulation, Heparin-induced thrombocytopenia, Fibrinogen, Protein C, The Queen's Award for Enterprise: Innovation (Technology) (2011), Bleeding time, Factor, Activated protein C resistance, Factor X, Prothrombin time, Factor VIII, Prekallikrein, Factor V, Antithrombin, POC, Protein S, Factor XII, Factor XI, Fine chemical, Plasmin

The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.
  • New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation.
  • Coagulation testing will also become more standardized, offering opportunities for quality control products and services.